
|Articles|June 11, 2008
Dry AMD trial doses first patient
US firm Acucela Inc. has dosed the first patient in the Phase I trial of its lead candidate, ACU-02, an oral compound which is in development for dry age-related macular degeneration (AMD).
Advertisement
US firm Acucela Inc. has dosed the first patient in the Phase I trial of its lead candidate, ACU-02, an oral compound which is in development for dry age-related macular degeneration (AMD).
The trial, to determine safety, tolerability and pharmacokinetics of the oral treatment, is a single-site, double-masked, placebo-controlled, single ascending-dose study treating healthy subjects.
ACU-02 reduces the accumulation of A2E, thereby interrupting the pathophysiology of AMD and preserving retinal cells.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Why ST-100 is expanding from dry eye into corneal wound healing
2
Eichenbaum Acorns: Building the private academic model with Jeffrey S. Heier, MD
3
ONL Therapeutics completes enrollment in Phase 2 GALAXY trial for geographic atrophy
4
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
5
















